Matricelf

Company Overview

Snapshot

Founded in April 2019, Matricelf operates with 11–50 employees. The company has raised over $10 million across 4 funding rounds from 2 investors. A significant milestone was achieved in June 2021 when Matricelf became publicly listed on the TASE.

Business overview

Matricelf is a Health Tech & Life Sciences company focused on regenerative medicine. It develops a personalized platform for autologous engineered tissue, utilizing a proprietary decellularization process to create thermo-responsive hydrogels and reprogrammed induced pluripotent stem cells (iPSCs). This technology is designed to differentiate into desired functional tissues, aiming to treat various medical conditions including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction. The company operates within the Pharma & Medical Biotechnology sector, specifically in Biomaterials & Tissue Engineering, serving healthcare providers, biotechnology, and pharmaceutical industries.

Strategic signal

In June 2026, Matricelf advanced towards its first-in-human trial by initiating a GMP manufacturing program and successfully completing a GLP safety study for its personalized engineered tissue implants for spinal cord injury. This signals strong progress in the company's clinical development pipeline and validates its regenerative medicine platform, indicating a potential near-term transition to human trials and significant de-risking for investors.

Company Intelligence Q&A

What is Matricelf's primary focus in regenerative medicine?

Matricelf focuses on developing personalized autologous engineered tissue implants for treating various medical conditions, including spinal cord injuries, age-related macular degeneration, and Parkinson's disease, utilizing a proprietary decellularization process.

What was a key development for Matricelf in March 2026?

In March 2026, Matricelf reported positive RNA sequencing results demonstrating a promising safety profile for its personalized spinal cord implant. Additionally, the company signed an MOU to establish a subsidiary for the commercialization of Parkinson's disease therapy and entered a strategic collaboration with Japan's CiRA Foundation to advance next-generation regenerative manufacturing.

When did Matricelf become a public company?

Matricelf became a public company in June 2021, listing on the TASE.

What significant corporate governance change occurred in February 2026?

In February 2026, Matricelf appointed Ron Mayron as the new Chairman of the Board.

What was a notable achievement for Matricelf in March 2025?

In March 2025, Matricelf announced a global collaboration with Cellino to scale personalized spinal cord injury treatments.